• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

Here's How Patient Investors Could Buy Vertex Pharmaceuticals

The short-term charts of VRTX suggest that this stock can see further sideways to lower price action in the weeks ahead.
By BRUCE KAMICH
Aug 18, 2020 | 10:25 AM EDT
Stocks quotes in this article: VRTX

The "Lightning Round" segment of Mad Money is a viewer favorite. Callers get the opportunity to ask Jim Cramer about stocks they are interested in. Monday night one caller asked about Vertex Pharmaceuticals (VRTX) : "You want to buy Vertex. This one is getting better and better," said Cramer. 

 
Let's check out the charts. 
 
In this daily bar chart of VRTX, below, we can see that prices rallied into July and stalled out before pulling back this month. Prices broke below the 50-day moving average line and the slope of the line has turned negative. VRTX is still above the rising 200-day moving average line which intersects down below $250 now. The trading volume has been active since March but has been slowly decreasing.
 
The On-Balance-Volume (OBV) line shows a peak in early June and a slow descent into August telling us that sellers of VRTX have been more aggressive.
 
The trend-following Moving Average Convergence Divergence (MACD) oscillator is below the zero line in sell territory but this indicator is getting close to an upside crossover for a cover shorts buy signal.  
 
 
In this weekly bar chart of VRTX, below, we can see that prices made a large sideways consolidation pattern in 2018 and 2019. Prices broke out on the upside in late 2019 and we can see a pretty good mark-up rally. VRTX is above the rising 40-week moving average line.
 
The weekly OBV line has been rising the past three years which is very bullish, but we can see that the line has leveled off a little since July telling us that aggressive buyers are taking a short pause.
 
The weekly MACD oscillator has turned down in a take profits sell signal. 
 
 
In this Point and Figure chart of VRTX, below, we used weekly close only price data. Here the software is projecting a potential longer-term price target in the $392 area. 
 
 
Bottom line strategy: The short-term charts of VRTX suggest that this stock can see further sideways to lower price action in the weeks ahead. Eventually the selling pressure should run its course and we should see the start of renewed buying and a rising OBV line.
 
Investors who like VRTX should wait for the OBV line to bottom and begin climbing again before probing the long side. Our weekly Point and Figure chart suggests that VRTX could rally close to $400 in the months ahead. 
Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Drug Approvals | Investing | Stocks | Technical Analysis | Trading | Pharmaceuticals | Mad Money

More from Investing

Does the Big Bounce Mean More to Come? Let's See What Drove the Move

James "Rev Shark" DePorre
Jun 24, 2022 4:42 PM EDT

Much of the rally can be attributed to structural reasons, not fundamentals, technicals, or even macro ones.

MongoDB Is Poised for a Rally

Bruce Kamich
Jun 24, 2022 2:15 PM EDT

Here's our initial upside price target for MDB which provides a general purpose database platform.

See That Down the Road? It's the Big 'Green' Bubble, Ready to Pop

Jim Collins
Jun 24, 2022 1:30 PM EDT

Environmental, social, and corporate governance has created a monster and gullible investors should hit the brakes on their EVs and run from the Washington technocrats while they have the chance.

Treat Becton, Dickinson and Company With Care

Bruce Kamich
Jun 24, 2022 1:25 PM EDT

BDX gets an upgrade, but are the charts healthy enough to recommend?

When Times Are Tough, These 3 Mega-Caps Should Deliver the Dividends

Bob Ciura
Jun 24, 2022 1:00 PM EDT

Here's why in recessions and bear markets, the right mega-cap stocks can offer security -- and good yields.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:55 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    The 10 personality traits of successful traders an...
  • 12:08 PM EDT STEPHEN GUILFOYLE

    Stocks Under $10

    As a Portfolio Name Agrees to a Merger, Here's Our...
  • 10:44 AM EDT PAUL PRICE

    My Very Best Pick for the Next 12 Months

    American Woodmark . It rarely gets better than th...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2022 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login